Applied Therapeutics, Inc. (APLT) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
545 Fifth Avenue
New York City, NY 10017
United States of America (the)
Phone
212 220 9226
Sector
Healthcare
Industry
Biotechnology
Employees
35
First IPO Date
May 14, 2019
| Name | Title | Pay | Year Born |
| Les D. Funtleyder | Interm Chief Executive Officer, Chief Financial Officer, Principal Financial Officer & Director | 768,846 | 1970 |
| Corwin Dale Hooks | Chief Commercial Officer | 636,739 | 1967 |
| Evan Prescott Bailey | Chief Medical Officer | 860,761 | N/A |
| Todd F. Baumgartner | Chief Regulatory Officer | 0 | N/A |
| Catherine Thorpe | Interim Chief Accounting Officer | 0 | 1964 |
| Dottie Caplan | Executive Vice President of Patient Advocacy & Government Affairs. | 0 | N/A |
| Reena Thomas Colacot | Head of Quality | 0 | N/A |
| Constantine Chinoporos | Chief Operating Officer & Chief Business Officer | 0 | 1966 |
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for cardiovascular conditions, galactosemia, and various diabetes-related complications. The company's primary drug candidate, AT-007, has successfully concluded Phase 1/2 studies for galactosemia in healthy adult volunteers and is presently in a pediatric clinical study for the same indication in children. Additionally, AT-007 is being investigated for its potential to address sorbitol dehydrogenase deficiency and phosphomannomutase enzyme-CDG. Another key compound, AT-001, is currently undergoing pivotal Phase III clinical trials. This therapy is being evaluated for its efficacy in treating both diabetic cardiomyopathy and diabetic peripheral neuropathy. Beyond its clinical pipeline, the company also maintains an early-stage preclinical portfolio. This includes AT-003, which is being developed for diabetic retinopathy, and AT-104. AT-104 is a PI3K inhibitor specifically designed to target T-Cell Acute Lymphoblastic Leukemia, a rare form of blood cancer. Applied Therapeutics, Inc. was established in 2016 and operates from its headquarters in New York City.